Palo Alto, Calif. -- Shares of Palo Alto-based Affymax rose nearly 30% by late Friday after the biopharmaceutical firm priced its $92.5 million initial public offering (IPO). The company priced its 3.7 million shares at $25 each -- both higher than its expectations of 3.5 million shares at $22-$24 each. Trading under the symbol "AFFY" on the Nasdaq Global Market, company shares were trading at around $32.50 late Friday. Affymax's lead product candidate, Hematide, is designed to treat anemia ssociated with chronic kidney disease and cancer.
http://biz.yahoo.com/prnews/061214/sfth082.html?.v=60
http://www.affymax.com/